Zydus Cadila, one of India leading healthcare companies and a global healthcare provider, has acquired Etna Biotech, the wholly owned subsidiary of the Dutch biopharma company, Crucell N.V. The deal, which marks Zydus Cadila's first acquisition in the research space, offers the group a highly evolved research platform for developing new vaccines and technology.
Crucell which was focused on biologicals entered the vaccine space with the acquisition of Berna. Biotech, a globally renowned, specialized vaccine company. Etna was the dedicated research and development wing of Berna Biotech.Etna Biotech headquartered in Catania, Italy, focuses on research and development of vaccines. Currently, Etna Biotech has several innovative technologies and vaccines at different development stages in its pipeline. Prominent among those are the programs for developing vaccines against hepatitis using the virosome vaccine technology platform; and against Malaria and HPV using the measles technology platform.
The need for specialized technology and cutting edge research, has resulted in relatively limited competition and have posed high entry harriers for players in the field of vaccines. With the global vaccine industry forecasted to grow by nearly 18% by 2010, which is roughly three times the growth of the global pharmaceutical industry, research and development of vaccines have emerged as a major focus area in recent times.
The company made this announcement during the trading hours today, 11 November 2008.
No comments:
Post a Comment